1 active not recruiting, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Standard disease-directed therapy: new trials by email Literature Review of Standard disease-directed therapy trials Research Report on Standard disease-directed therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-10-30 |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms INCB160058, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Active not recruiting | Incyte Corporation | 37 | 2024-08-08 | 2026-08-12 |
Myeloproliferative Disorders (2) · Primary Myelofibrosis (2) · Polycythemia Vera (1) · Thrombocythemia, Essential (1)
Canada (2) · France (2) · Germany (2) · Italy (2) · United Kingdom (2) · United States (2) · Australia (1) · Belgium (1) · Japan (1) · Norway (1) · South Korea (1) · Spain (1) · Switzerland (1)